Crispr Therapeutics Ag

Mary-Lee Dequeant

Demetrios Kalaitzidis

Mohammed Ghonime

Lalit Kumar

A population of genetically engineered T cells, comprising a disrupted Reg1 gene and/or a disrupted TGFBRII gene. Such genetically engineered T cells may comprise further genetic modifications, for example, a disrupted CD70 gene. The population of genetically engineered T cells exhibit one or more of (a) improved cell growth activity; (b) enhanced persistence; and (c) reduced T cell exhaustion, (d) enhanced cytotoxicity activity, (e) resistant to inhibitory effects induced by TGF-b, and (f) resistant to inhibitory effects by fibroblasts and/or inhibitory factors secreted thereby, as compared to non-engineered T cell counterparts.

Genetically engineered T cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence

High affinity antibodies capable of binding to a single-chain variable fragment (scFv) of anti-CD70 antibody, for example, the scFv expressed on cell surface as a portion of a chimeric antigen receptor (CAR). Also provided herein are methods for producing such anti-scFv antibodies and methods of using the antibodies disclosed herein for detecting, for example, T cells expressing an anti-CD70 CAR that comprise the scFv as an extracellular domain.

Anti-idiotype antibodies targeting anti-CD70 chimeric antigen receptor

Genetically engineered T cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistence

Genetically engineered t cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence

Genetically engineered t cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistence

Growing community of inventors

Cambridge, MA, United States of America

Mary-Lee Dequeant